A Darwinian approach to Huntington's disease: Subtle health benefits of a neurological disorder

Medical Hypotheses

Volumn 69, Issue 6, 2007, Pages 1183-1189

  Eskenazi, Benjamin R ^a   Wilson Rich, Noah S ^a   Starks, Philip T ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SUSCEPTIBILITY; FITNESS; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; IMMUNOREACTIVITY; NATURAL SELECTION; PRIORITY JOURNAL; REPRODUCTION;

ALLELES; HUMANS; HUNTINGTON DISEASE; IMMUNE SYSTEM; MODELS, THEORETICAL; MUTATION; NEURODEGENERATIVE DISEASES; SELECTION (GENETICS); SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35448995288     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.02.046     Document Type: Article

References (70)

1. Caramins M., Halliday G., McCusker E., and Trent R.J. Genetically confirmed clinical Huntington's disease with no observable cell loss. J Neurol Neurosur Psychiat 74 (2003) 968-970
2. Calabresi P., De Murtas M., and Bernardi G. The neostriatum beyond the motor function: experimental and clinical evidence. Neuroscience 78 1 (1997) 39-60
3. Huber S.J., and Paulson G.W. Memory impairment associated with progression of Huntington's disease. Cortex 23 (1987) 275-283
4. In: Harper P.S. (Ed). Huntington's disease. 2nd ed. (1996), W.B. Saunders, Philadelphia (PA)
5. Watt D.C., and Seller A. A clinico-genetic study of psychiatric disorder in Huntington's chorea. Psychol Med Suppl. 23 (1993) 1-46
6. Lovestone S., Hodgson S., Sham P., Differ A.M., and Levy R. Familial psychiatric presentation of Huntington's disease. J Med Genet 33 (1996) 128-131
7. Mahant N., McCusker E.A., Byth K., Graham S., and Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology 61 (2003) 1085-1092
8. Paulsen J.S., Hoth K.F., Nehl C., and Stierman L. Critical periods of suicide risk in Huntington's disease. Am J Psychol 162 4 (2005) 725-731
9. Almqvist E., Spence N., Nichol K., et al. Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease. Hum Mol Genet 4 (1995) 207-214
10. Almqvist E., Elterman D., MacLeod P., and Hayden M. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet 60 (2001) 198-205
11. n repeat in Huntington's disease patients of Greek origin. J Hum Genet 3 (1995) 228-234
12. Brinkman R.R., Mezei M.M., Theilmann J., Almqvist E., and Hayden M.R. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60 (1997) 1202-1210
13. Trottier Y., Biancalana V., and Mandel J.L. Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J Med Genet 31 (1994) 377-382
14. Leeflang E.P., Tavare S., Marjoram P., et al. Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism. Hum Mol Genet 8 (1999) 173-183
15. De Rooij K.E., De Koning Gans P.A., Skraastad M.I., et al. Dynamic mutation in Dutch Huntington's disease patients: increased paternal repeat instability extending to within the normal size range. J Med Genet 30 (1993) 996-1002
16. Huntington Disease Genetic Testing Working Group. Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 62 5 (1998) 1243-1247
17. Rubinsztein D.C., Amos W., Leggo J., et al. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. Nat Genet 7 (1994) 525-530
18. Nesse R.M., and Williams G.C. Why we get sick: the new science of Darwinian medicine (1994), Times Books, New York
19. Goldberg Y.P., Kremer B., Andrew S.E., et al. Molecular analysis of new mutations causing Huntington disease: intermediate alleles and sex of origin effects. Nat Genet 5 (1993) 173-179
20. Ramos-Arroyo M.A., Moreno S., and Valiente A. Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing. J Neurol Neurosur Psychiat 76 3 (2005) 337-342
21. Marx R.N. Huntington's chorea in Minnesota. Adv Neurol 1 (1973) 237-243
22. Shokeir M.H. Investigation on Huntington's disease in the Canadian Prairies. II. Fecundity and fitness. Clin Genet 7 (1975) 349-353
23. Stevens DL. Huntington's chorea: a demographic, genetic, and clinical study. MD Thesis, University of London; 1976.
24. Walker D.A., Harper P.S., Newcombe R.G., and Davies K. Huntington's chorea in South Wales: mutation, fertility, and genetic fitness. J Med Genet 20 (1983) 12-17
25. Pridmore S.A., and Adams G.C. The fertility of HD- affected individuals in Tasmania. Aust NZ J Psychiat 25 (1991) 262-264
26. Dewhurst K., Oliver J.E., and McKnight A.L. Socio-psychiatric consequences of Huntington's disease. Brit J Psychiat 116 (1970) 255-258
27. Postrach F. Juvenile Huntington chorea with persistent sexual deviance: a case report. Psychiat Neurol Med Psychol 41 (1989) 746-750
28. Rich S.S., and Ovsiew F. Leuprolide acetate for exhibitionism in Huntington's disease. Movement Disord 9 (1994) 353-357
29. Lawrence A.D., Hodges J.R., Rosser A.E., et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 121 7 (1998) 1329-1341
30. Dawson S., Kristjanson L.J., Toye C.M., and Flett P. Living with Huntington's disease: need for supportive care. Nurs Health Sci 6 (2004) 123-130
31. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., and Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation. J Neurol 251 (2004) 935-942
32. Wolff J.O., and Macdonald D.W. Promiscuous females protect their offspring. Trends Ecol Evol 19 (2004) 128-134
33. Sorensen S.A., Fenger K., and Olsen J.H. Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract?. Cancer 86 (1999) 1342-1346
34. Lopreato J., and Yu M. Human fertility and fitness optimization. Ethol Sociobiol 9 (1988) 269-289
35. Fananas L., and Bertranpetit J. Reproductive rates in families of schizophrenic patients in a case-control study. Acta Psychiat Scand 91 (1995) 202-204
36. McGrath J.J., Hearle J., Jenner L., Plant K., Drummond A., and Barkla J.M. The fertility and fecundity of patients with psychoses. Acta Psychiat Scand 99 (1999) 441-446
37. In: Ellis L.E. (Ed). Reproductive and interpersonal aspects of dominance and status. Social stratification and socioeconomic inequality 2 (1994) 260
38. De Laurenzi V., and Melino G. Evolution of functions within the p53/p63/p73 family. Ann NY Acad Sci 926 (2000) 90-100
39. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
40. Choisy-Rossi C., Reisdorf P., and Yonish-Rouach E. Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death. Toxicol Lett 102-103 (1998) 491-496
41. Takaoka A., Hayakawa S., Yanai H., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
42. Baek K.H., Shin H.J., Yoo J.K., et al. p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest. J Leukocyte Biol 73 (2003) 850-861
43. Lechpammer M., Lukac J., Lechpammer S., Kovacevic D., Loda M., and Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19 (2004) 114-120
44. Leavitt B.R., Wellington C.L., and Hayden M.R. Recent insights into the molecular pathogenesis of Huntington disease. Semin Neurol 19 (1999) 385-395
45. Li S.H., and Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20 (2004) 146-154
46. Harjes P., and Wanker E.E. The hunt for Huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28 (2003) 425-433
47. Rigamonti D., Bauer J.H., De-Fraja C., et al. Wild-type Huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20 (2000) 3705-3713
48. Davies S.W., Turmaine M., Cozens B.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
49. DiFiglia M., Sapp E., Chase K.O., et al. Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
50. Becher M.W., Kotzuk J.A., Sharp A.H., et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy - correlation between the density of inclusions and IT-15 CAG triplet repeat length. Neurobiol Dis 4 (1998) 387-397
51. Jana N.R., Zemskov E.A., Wang G.H., and Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal Huntingtin induces apoptosis by capsase activation through mitochondrial cytochrome c release. Hum Mol Genet 10 (2001) 1049-1059
52. Wyttenbach A., Carmichael J., Swartz J., et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 97 (2000) 2898-2903
53. Ambrose C.M., Duyao M.P., Barnes G., et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Gen 20 (1994) 27-38
54. Song C., Perides G., and Liu Y.F. Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 277 8 (2002) 6703-6707
55. Farrer L.A. Diabetes mellitus in Huntington disease. Clin Genet 27 (1984) 62-67
56. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 82 (2004) 510-529
57. Nakachi K., Eguchi H., and Imai K. Can teatime increase one's lifetime?. Ageing Res Rev 2 (2003) 1-10
58. Trettel F., Rigamonti D., Hilditch-Maguire P., et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9 (2000) 2799-2809
59. Bae B.-I., Xu H., Igarashi S., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 1 (2005) 29-41
60. Steffan J.S., Kazantsev A., Spasic-Boskovic O., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97 (2000) 6763-6768
61. Hackam A.S., Yassa A.S., Singaraja R., et al. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J Biol Chem 275 (2000) 41299-41308
62. Frontali M., Sabbadini G., Novelletto A., et al. Genetic fitness in Huntington's disease and spinocerebellar ataxia 1: a population genetics model for CAG repeat expansions. Ann Hum Genet 60 (1996) 423-435
63. Forbes S. Pregnancy sickness and embryo quality. Trends Ecol Evol 17 (2002) 115-120
64. Weinert B.T., and Timiras P.S. Invited review: theories of aging. J Appl Physiol 95 4 (2003) 1706-1716
65. Utermann G., Vogelberg K.H., and Steinmetz A. Polymorphism of apolipoprotein E.II. Genetics of hyperlipoproteinemia type III. Clin Genet 15 1 (1979) 37-62
66. Ewald P.W. Evolution of infectious disease (1994), Oxford University Press, New York
67. In: Stearns S.C. (Ed). Evolution in health and disease (1999), Oxford University Press, New York
68. Trevathan W.R., Smith E.O., and McKenna J.J. Evolutionary medicine (1999), Oxford University Press, Cambridge
69. Flaxman S.M., and Sherman P.W. Morning sickness: a mechanism for protecting mother and embryo. Q Rev Biol 75 (2000) 113-148
70. Nesse R.M., and Schiffman J.D. Evolutionary biology in the medical school curriculum. Bioscience 53 (2003) 585-587